Estrella Immunopharma Stock (NASDAQ:ESLA)
Previous Close
$1.61
52W Range
$0.63 - $1.90
50D Avg
$1.13
200D Avg
$1.04
Market Cap
$64.86M
Avg Vol (3M)
$88.10K
Beta
0.39
Div Yield
-
ESLA Company Profile
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.